Schistosome incubation product (SIP) obtained from Schistosoma mansoni was tested on mast cell degranulation in vitro or in vivo elicited by chemical compounds or anaphylactic reactions. Normal mast cells from Wistar rats were labeled with 3H-serotonin and incubated with the SIP. Serotonin release normally induced by the chemical compounds 48/80, polymyxin B or an anaphylactic system (ovalbumin-antiovalbumin) was inhibited when mast cells were preincubated with the SIP. Cutaneous reactions elicited by the compound 48/80 or polymyxin B and passive or active cutaneous anaphylactic reactions, were inhibited by the intradermal injection of the SIP before the challenge. The anaphylactic shock by ovalbumin was also inhibited in guinea pigs by a previous intraperitoneal injection of the SIP. This inhibitor appeared dialysable, heat resistant and soluble in trichloroacetic acid (TCA). The inhibitory activity was found in the fraction eluted from an antischistosome immunosorbent. However, no inhibition of cutaneous reactions was observed with the circulating (TCA-soluble, thermostable) M antigen previously described and purified from schistosomes. No effect of the SIP was observed on the growth of HeLa cells or the J 111 human monocytic cell line. The increase of intracellular cAMP levels in mast cells incubated with the SIP suggests that modulation of cAMP is involved in the mechanism of inhibition. The SIP inhibited also the mast cell-dependent eosinophil cytotoxicity for schistosomula sensitized with IgG2a antibody. The SIP appeared to act selectively on mast cell degranulation without effect on eosinophils or the mast cell mediators. This inhibitor, denominated schistosome-derived inhibitory factor, released by the parasite, which acts on mast cells could partly explain the low incidence of clinical allergic manifestations observed in parasitic diseases and might represent an escape mechanism of the parasite to the antibody-dependent eosinophil cytotoxicity mechanism.

This content is only available via PDF.
© 1980 S. Karger AG, Basel
1980
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.